- Report
- May 2023
- 215 Pages
Global
From €3295EUR$3,600USD£2,801GBP
- Report
- May 2023
- 93 Pages
Europe
From €1373EUR$1,500USD£1,167GBP
- Report
- May 2023
- 93 Pages
Middle East, Africa
From €1373EUR$1,500USD£1,167GBP
- Report
- May 2023
- 83 Pages
North America
From €1373EUR$1,500USD£1,167GBP
- Report
- August 2023
- 180 Pages
Global
From €3433EUR$3,750USD£2,917GBP
- Report
- October 2022
- 307 Pages
Global
From €2289EUR$2,500USD£1,945GBP
- Report
- February 2023
- 385 Pages
Global
From €2288EUR$2,499USD£1,944GBP
€3268EUR$3,570USD£2,777GBP
- Report
- November 2021
- 220 Pages
Global
From €2379EUR$2,598USD£2,022GBP
€3398EUR$3,712USD£2,888GBP
The Oral Antiviral market is a subset of the Infectious Diseases Drugs market, which includes medications used to treat a variety of bacterial, viral, and fungal infections. Oral antivirals are medications taken by mouth to treat viral infections, such as herpes, HIV, and influenza. These drugs work by interfering with the virus’s ability to replicate, thus preventing it from spreading and causing further damage. Oral antivirals are often used in combination with other treatments, such as topical creams or injections, to maximize their effectiveness.
Oral antivirals are widely used in the treatment of many viral infections, and their use is increasing as new drugs are developed. They are generally well-tolerated and have fewer side effects than other treatments. However, they can be expensive and may not be available in all countries.
Some companies in the Oral Antiviral market include Gilead Sciences, Merck, GlaxoSmithKline, and Bristol-Myers Squibb. Show Less Read more